Document is current
Any future updates will be listed below
-
Authors
Moding, Everett J. https://orcid.org/0000-0001-7913-5351
Liu, Yufei
Nabet, Barzin Y. https://orcid.org/0000-0002-4824-3533
Chabon, Jacob J.
Chaudhuri, Aadel A. https://orcid.org/0000-0003-3115-3061
Hui, Angela B.
Bonilla, Rene F.
Ko, Ryan B. https://orcid.org/0000-0002-2123-9702
Yoo, Christopher H. https://orcid.org/0000-0003-2132-8956
Gojenola, Linda
Jones, Carol D.
He, Jianzhong
Qiao, Yawei
Xu, Ting
Heymach, John V.
Tsao, Anne
Liao, Zhongxing
Gomez, Daniel R.
Das, Millie
Padda, Sukhmani K.
Ramchandran, Kavitha J.
Neal, Joel W.
Wakelee, Heather A.
Loo, Billy W. Jr https://orcid.org/0000-0002-2521-0544
Lin, Steven H. https://orcid.org/0000-0003-4411-0634
Alizadeh, Ash A. https://orcid.org/0000-0002-5153-5625
Diehn, Maximilian https://orcid.org/0000-0003-2032-0581
-
Funding
Funding for this research was provided by:
Radiological Society of North America
American Society for Radiation Oncology Stanford Radiation Oncology Kaplan Fellowship
Virginia and D.K. Ludwig Fund for Cancer Research
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA188298, R01CA188298, 1-DP2-CA186569)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
CRK Faculty Scholar Fund
- License Information
-
More Information
Article History
Received: 21 September 2019
Accepted: 2 December 2019
First Online: 20 January 2020
Competing interests
: E.J.M., Y.L., B.Y.N., J.J.C., A.B.H., R.F.B, R.B.K., C.H.Y., L.G., C.D.J., J.H., Y.Q., T.X., J.V.H., A.T., Z.L., D.R.G., S.K.P., K.J.R. and B.W.L. declare no competing interests. A.A.C. has served as an advisor/consultant for Roche, Tempus Labs, Geneoscopy and Oscar Health, and has received speaker honoraria from Roche, Varian Medical Systems and Foundation Medicine. M.Das has received research funding from Verily, AbbVie, United Therapeutics and Celgene and has served as a consultant and received honoraria from Bristol-Myers Squibb and AstraZeneca. J.W.N. has served as an advisor/consultant for ARIAD Pharmaceuticals/Takeda, AstraZeneca, Genentech/Roche, Eli Lilly, Exelixis, Loxo Oncology and Jounce. J.W.N. has received research funding from Genentech/Roche, Merck, Novartis, Boehringer Ingelheim, Exelixis, ARIAD Pharmaceuticals/Takeda and Nektar. H.A.W. has served on the advisory board for AstraZeneca, Xcovery, Janssen, Mirati Therapeutics, Merck, Takeda and Genentech/Roche and has received compensation from AstraZeneca, Xcovery, Janssen and Mirati. H.A.W. has received research funding from ACEA Biosciences, Arrys Therapeutics, AstraZeneca/MedImmune, BMS, Celgene, Clovis Oncology, Exelixis, Genentech/Roche, Gilead Sciences, Eli Lilly, Merck, Novartis, Pfizer, Pharmacyclics and Xcovery. S.H.L. receives grant funding from Hitachi Chemical Diagnostics, Genentech and BeyondSpring Pharmaceuticals, an honorarium from Varian Medical Systems and has served on the advisory board for AstraZeneca and BeyondSpring Pharmaceuticals. A.A.A. and M.Diehn are coinventors on patent applications related to CAPP-Seq. A.A.A. has equity in Forty Seven and CiberMed and has served as a consultant for Roche, Genentech, Chugai Pharma and Pharmacyclics. M.Diehn has equity in CiberMed, has received research funding from Varian Medical Systems and has served as a paid consultant for Roche, AstraZeneca, BioNTech, Illumina and RefleXion and as an unpaid consultant for Genentech.
